| Detection of autism spectrum disorder-related pathogenic trio variants by a novel structure-based approach. | Detection of autism spectrum disorder-related pathogenic trio variants by a novel structure-based approach.
Rao S, Sadybekov A, DeWitt DC, Lipka J, Katritch V, Herring BE., Free PMC Article | 04/5/2024 |
| Pathogenic TRIO variants associated with neurodevelopmental disorders perturb the molecular regulation of TRIO and axon pathfinding in vivo. | Pathogenic TRIO variants associated with neurodevelopmental disorders perturb the molecular regulation of TRIO and axon pathfinding in vivo.
Bonnet M, Roche F, Fagotto-Kaufmann C, Gazdagh G, Truong I, Comunale F, Barbosa S, Bonhomme M, Nafati N, Hunt D, Rodriguez MP, Chaudhry A, Shears D, Madruga M, Vansenne F, Curie A, Kajava AV, Baralle D, Fassier C, Debant A, Schmidt S. | 05/30/2023 |
| Autoinhibition of the GEF activity of cytoskeletal regulatory protein Trio is disrupted in neurodevelopmental disorder-related genetic variants. | Autoinhibition of the GEF activity of cytoskeletal regulatory protein Trio is disrupted in neurodevelopmental disorder-related genetic variants.
Bircher JE, Corcoran EE, Lam TT, Trnka MJ, Koleske AJ., Free PMC Article | 10/29/2022 |
| Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1. | Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1.
Bandekar SJ, Chen CL, Ravala SK, Cash JN, Avramova LV, Zhalnina MV, Gutkind JS, Li S, Tesmer JJG., Free PMC Article | 09/17/2022 |
| Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA. | Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA.
Wang J, Yuan L, Xu X, Zhang Z, Ma Y, Hong L, Ma J., Free PMC Article | 04/16/2022 |
| More evidence on TRIO missense mutations in the spectrin repeat domain causing severe developmental delay and recognizable facial dysmorphism with macrocephaly. | More evidence on TRIO missense mutations in the spectrin repeat domain causing severe developmental delay and recognizable facial dysmorphism with macrocephaly.
Kloth K, Graul-Neumann L, Hermann K, Johannsen J, Bierhals T, Kortüm F. | 01/8/2022 |
| Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners. | Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners.
Johnstone EKM, Abhayawardana RS, See HB, Seeber RM, O'Brien SL, Thomas WG, Pfleger KDG. | 09/18/2021 |
| Genetics of physiological dysregulation: findings from the long life family study using joint models. | Genetics of physiological dysregulation: findings from the long life family study using joint models.
Arbeev KG, Bagley O, Ukraintseva SV, Wu D, Duan H, Kulminski AM, Stallard E, Christensen K, Lee JH, Thyagarajan B, Zmuda JM, Yashin AI., Free PMC Article | 02/27/2021 |
| Novel loss-of-function variants in TRIO are associated with neurodevelopmental disorder: case report. | Novel loss-of-function variants in TRIO are associated with neurodevelopmental disorder: case report.
Schultz-Rogers L, Muthusamy K, Pinto E Vairo F, Klee EW, Lanpher B., Free PMC Article | 01/9/2021 |
| The Rho guanine nucleotide exchange factor Trio is required for neural crest cell migration and interacts with Dishevelled. | The Rho guanine nucleotide exchange factor Trio is required for neural crest cell migration and interacts with Dishevelled.
Kratzer MC, Becker SFS, Grund A, Merks A, Harnoš J, Bryja V, Giehl K, Kashef J, Borchers A. | 12/26/2020 |
| Synaptic Kalirin-7 and Trio Interactomes Reveal a GEF Protein-Dependent Neuroligin-1 Mechanism of Action. | Synaptic Kalirin-7 and Trio Interactomes Reveal a GEF Protein-Dependent Neuroligin-1 Mechanism of Action.
Paskus JD, Tian C, Fingleton E, Shen C, Chen X, Li Y, Myers SA, Badger JD 2nd, Bemben MA, Herring BE, Roche KW., Free PMC Article | 10/3/2020 |
| demonstrates distinct clinical and molecular disorders clustering in the GEFD1 and seventh spectrin repeat domains and highlights the importance of tight control of TRIO-RAC1 signaling in neuronal development | Opposite Modulation of RAC1 by Mutations in TRIO Is Associated with Distinct, Domain-Specific Neurodevelopmental Disorders.
Barbosa S, Greville-Heygate S, Bonnet M, Godwin A, Fagotto-Kaufmann C, Kajava AV, Laouteouet D, Mawby R, Wai HA, Dingemans AJM, Hehir-Kwa J, Willems M, Capri Y, Mehta SG, Cox H, Goudie D, Vansenne F, Turnpenny P, Vincent M, Cogné B, Lesca G, Hertecant J, Rodriguez D, Keren B, Burglen L, Gérard M, Putoux A, C4RCD Research Group, Cantagrel V, Siquier-Pernet K, Rio M, Banka S, Sarkar A, Steeves M, Parker M, Clement E, Moutton S, Tran Mau-Them F, Piton A, de Vries BBA, Guille M, Debant A, Schmidt S, Baralle D., Free PMC Article | 05/9/2020 |
| study found TRIO somatic frameshift mutations in gastric cancers (GCs) and colorectal cancers (CRCs) with MSI-H, but not in CRCs and GCs with MSS (p < 0.001); all of the mutations were deletion or duplication mutations in the repeats that would cause premature stops | TRIO Gene Encoding Trio Rho Guanine Nucleotide Exchange Factor Harbors Frameshift Mutations of in Gastric and Colorectal Cancers.
Choi EJ, Kim MS, Yoo NJ, Lee SH. | 09/7/2019 |
| results highlight a role for the C-terminal 15 amino acids in the membrane association of TGAT and the subsequent activation of RhoA and actin polymerization by TGAT | The C-terminus of the oncoprotein TGAT is necessary for plasma membrane association and efficient RhoA-mediated signaling.
van Unen J, Botman D, Yin T, Wu YI, Hink MA, Gadella TWJ Jr, Postma M, Goedhart J., Free PMC Article | 02/9/2019 |
| Results revealed that TRIO high expression levels in cervical cancer were correlated with lymph node metastasis. Its inhibition significantly decreased the migration and invasion abilities of cervical cancer cells through the RhoA/ROCK signaling pathway. | Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells.
Hou C, Zhuang Z, Deng X, Xu Y, Zhang P, Zhu L. | 09/8/2018 |
| Trio plays a role in activating Rac1 in podocytes both in basal conditions and when stimulated with TGFbeta1. We speculate that Trio may have dual roles; it may play important roles in podocyte development but it may also regulate pathological Rac1 hyperactivation in the context of TGFbeta1-mediated podocyte injury and glomerulosclerosis. | The Role of Trio, a Rho Guanine Nucleotide Exchange Factor, in Glomerular Podocytes.
Maier M, Baldwin C, Aoudjit L, Takano T., Free PMC Article | 08/11/2018 |
| Genetic damage to both TGEF domains altered TRIO catalytic activity, decreasing TGEF1 activity and increasing TGEF2 activity. | Neurodevelopmental disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP exchange factor activity.
Katrancha SM, Wu Y, Zhu M, Eipper BA, Koleske AJ, Mains RE., Free PMC Article | 05/26/2018 |
| A recurrent rearrangement involving TRIO with various partners was identified in 5.1% of non-translocation-related sarcoma cases. TRIO translocations are either intrachromosomal with TERT or interchromosomal with LINC01504 or ZNF558. All translocations led to a truncated TRIO protein either directly or indirectly by alternative splicing. TRIO rearrangement is associated with a modified transcriptomic program. | Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas.
Delespaul L, Lesluyes T, Pérot G, Brulard C, Lartigue L, Baud J, Lagarde P, Le Guellec S, Neuville A, Terrier P, Vince-Ranchère D, Schmidt S, Debant A, Coindre JM, Chibon F. | 03/10/2018 |
| Study identifies a large cluster of de novo mutations in the GEF1 domain of Trio in whole-exome sequencing data from individuals with autism spectrum disorder. | An autism spectrum disorder-related de novo mutation hotspot discovered in the GEF1 domain of Trio.
Sadybekov A, Tian C, Arnesano C, Katritch V, Herring BE., Free PMC Article | 01/13/2018 |
| The findings provide a mechanism for the presynaptic targeting of Trio and support a model in which Piccolo and Bassoon play a role in regulating neurotransmission through interactions with proteins, including Trio, that modulate the dynamic assembly of F-actin during cycles of synaptic vesicle exo- and endocytosis. | Trio, a Rho Family GEF, Interacts with the Presynaptic Active Zone Proteins Piccolo and Bassoon.
Terry-Lorenzo RT, Torres VI, Wagh D, Galaz J, Swanson SK, Florens L, Washburn MP, Waites CL, Gundelfinger ED, Reimer RJ, Garner CC., Free PMC Article | 07/1/2017 |
| TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function. | TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function.
Ba W, Yan Y, Reijnders MR, Schuurs-Hoeijmakers JH, Feenstra I, Bongers EM, Bosch DG, De Leeuw N, Pfundt R, Gilissen C, De Vries PF, Veltman JA, Hoischen A, Mefford HC, Eichler EE, Vissers LE, Nadif Kasri N, De Vries BB., Free PMC Article | 12/17/2016 |
| our data show the importance of spatio-temporal regulation of the actin cytoskeleton through Trio and Rac1 at VE-cadherin-based cell-cell junctions in the maintenance of the endothelial barrier. | A local VE-cadherin and Trio-based signaling complex stabilizes endothelial junctions through Rac1.
Timmerman I, Heemskerk N, Kroon J, Schaefer A, van Rijssel J, Hoogenboezem M, van Unen J, Goedhart J, Gadella TW Jr, Yin T, Wu Y, Huveneers S, van Buul JD. | 06/4/2016 |
| Aberrant expression of TRIO might play an important role in hepatocellular carcinoma (HCC) through promoting cell proliferation and invasion, and TRIO may be a novel therapeutic target for the treatment of HCC | Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B, Fang J, Qu L, Cao Z, Zhou J, Deng B. | 03/5/2016 |
| Strong statistical evidence for a causal role of TRIO in neurodevelopmental and neuropsychiatric disorders. | Incorporating Functional Information in Tests of Excess De Novo Mutational Load.
Jiang Y, Han Y, Petrovski S, Owzar K, Goldstein DB, Allen AS., Free PMC Article | 10/31/2015 |
| TRIO controls Rac1 activation in dividing cells which counteracts MgcRacGAP function in cytokinesis. | Identification of a mitotic Rac-GEF, Trio, that counteracts MgcRacGAP function during cytokinesis.
Cannet A, Schmidt S, Delaval B, Debant A., Free PMC Article | 08/22/2015 |